<DOC>
	<DOCNO>NCT00551109</DOCNO>
	<brief_summary>The purpose study determine efficacy SA4503 compare placebo treatment subject major depressive disorder ( MDD ) . Secondary , evaluate safety SA4503 compare placebo subject MDD .</brief_summary>
	<brief_title>SA4503 8-Week Study Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>Further study detail provide M 's Science Corporation :</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>SA 4503</mesh_term>
	<criteria>Male female age 18 65 ( inclusive ) Diagnosis MDD accord Diagnostic Statistical Manual Mental Disorders ( DSM ) IV criterion shorten MINI evaluation HAMD17 score &gt; /= 21 severity score least 2 Item 1 ( depressed mood ) Screening Baseline Current depressive episode least 3 month duration , significant depress mood anhedonia 4 week prior Screening . Subjects receive fluoxetine within 1 month prior Baseline antidepressant within 2 week prior Baseline , unlicensed medication within 1 month Screening Subjects require psychotropic medication study medication Subjects start psychotherapy within 4 month prior Screening Subjects currently ( i.e. , month prior Screening ) meet DSMIV criterion bipolar syndrome psychotic depression severe somatoform eat disorder Subjects primary diagnosis anxiety Subjects regularly use sleep medication 3 time per week Subjects major psychiatric neurologic disorder MDD Subjects depression secondary stroke , cancer , severe medical illness Subjects history alcohol substance dependence ( within 1 year prior Screening )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>